|
Endpoint | Study populations | Compound | Study |
|
Improvement of peripheral nerve function | Diabetic rats | Salvianolic acid A | Yu et al. [79] |
Improvement of DN | Animal model of T2D | High-fat diet with menhaden oil | Coppey et al. [80] |
Improvement of DN | Patients with T2D and neuropathy | Tai Chi exercise |
Ahn and Song [81] |
Improvement of DN | T2DM patients | Beraprost sodium | Shin et al. [82] |
Improvement of DN | STZ-diabetic rats | Anandamide | Schreiber et al. [83] |
Improvement of peripheral nerve function | Mouse model of DPN | Thymosin β4 | Wang et al. [84] |
Improvement of chronic pain, including PDN | Rat model of STZ-induced PDN | Gastrodin | Sun et al. [85] |
Prevention of progression of DN | Patients enrolled in the aldose reductase inhibitor-diabetes complications | Epalrestat | Hotta et al. [86] |
Improvement of DN | STZ-diabetic rats | Gliclazide with curcumin | Attia et al. [87] |
Improvement of DN | STZ-diabetic rats | Bone marrow-derived mononuclear cells | Naruse et al. [88] |
Neuroprotection effect | In vitro model of high glucose-treated DRG neurons in culture | Galanin | Xu et al. [89] |
Improvement of DN | — | Baicalein |
Yorek [90] |
Improvement of neuropathic pain | Animal models of neuropathic pain | Brazilian armed spider venom toxin Tx3-3 | Dalmolin et al., [91] |
Neuroprotection effect Improvement of DN | STZ-diabetic rats | Magnesium-25 carrying porphyrin-fullerene nanoparticles | Hosseini et al. [92, 93] |
Maintaining health in diabetes | STZ-diabetic rats | Phosphodiesterase inhibitors | Milani et al. [94] |
Improve transplant outcome and graft function in diabetes | Isolated rat pancreatic islets | IMOD | Larijani et al. [95] |
Improve islet transplantation in diabetes | Isolated rat pancreatic islets | Cerium and yttrium oxide nanoparticles |
Hosseini and Abdollahi [96, 97] |
|